Servier Pharmaceuticals shared a post on LinkedIn:
“We’re excited to be here at ASH2025, where we’re sharing clinical and real-world data from our hematology portfolio, underscoring our leadership in IDH-mutated AML, MDS and other hematological malignancies.
At Servier, we’re committed to uncovering the full potential of our existing medicines while also advancing treatment options in our growing hematology pipeline. Visit us at booth 461 to connect with our team and explore our research.
Learn more here.”
Read More updates from ASH25 on OncoDaily.